Podcast episode 15 (in German)
Cagrilintide & CagriSema: The not-yet-approved weight-loss candidate fact-checked
July 5, 2026
Besides GLP-1, the body has a second satiety hormone that hardly anyone knows: amylin. Cagrilintide mimics it, and together with semaglutide, as CagriSema, it is among the strongest candidates in weight-loss research, still without approval as of July 2026.
What it is about
Amylin is released by the pancreas together with insulin after eating, slows gastric emptying and signals to the brainstem that you are full. The body’s own hormone is broken down within minutes, and its predecessor pramlintide had to be injected several times a day; cagrilintide, by contrast, is built to be long-acting. The episode explains why the combination with semaglutide addresses two independent satiety systems at once, what the trials up to the REDEFINE series show and how CagriSema compares with tirzepatide. The conclusion is a promising candidate of the next wave that is still in the approval process, and a gray market to which none of these data apply.
Key points
- Amylin was discovered in the late 1980s, first as deposits in the pancreas of people with type 2 diabetes; only later was it recognized as a satiety hormone.
- An early study by Lau and colleagues in the Lancet in 2021 found markedly more weight loss with cagrilintide plus semaglutide than with semaglutide alone.
- In the large REDEFINE trial series, CagriSema achieved more than 20 percent weight loss, putting it in the same range as tirzepatide.
- Some had expected around 25 percent; the more than 20 percent achieved falls just short of that and shows how high the bar in weight-loss medicine has now become.
- Amylin acts mainly on feeling full in the brainstem, GLP-1 more on appetite; the two mechanisms complement each other and reinforce each other in the trials.
- Tolerability is similar to that of other drugs in this class, mainly with nausea at the start; with strong weight loss some muscle is lost too, and protein and strength training counteract this.
- As of July 2026, CagriSema is not approved; what circulates on the gray market, often as self-mixed “DIY CagriSema”, is untested research material.
Where the data stop
Efficacy is well established in large trials, but robust long-term safety data will only come with broad use after approval. Whether amylin combinations can specifically spare muscle during weight loss is a line of research, not yet a result.
All numbers apply to the tested product in trials with medical supervision. For gray-market material there is neither tested quality nor reliable amounts, and self-mixed combinations have not been studied anywhere. Anyone hoping for CagriSema is better off being patient: the approval review is underway, as of July 2026, and after that a physician’s assessment decides whom it suits.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on July 5, 2026.
The topic in the database
- A long-acting amylin analog, alone or combined with semaglutide as CagriSema – two satiety systems in one injection, in phase 3 with more than 20…Cagrilintide / CagriSema
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.